Iregene Therapeutics Multicenter Clinical Trial for Novel Parkinson Disease Therapy

NouvNeu001 Hits Milestone with Successful Dosing of First Patient in iRegene Therapeutics' Multicenter Clinical Trial for Novel Parkinson's Disease Therapy

iRegene Therapeutics Co., Ltd (iRegene) recently made an important announcement regarding the progress of NouvNeu001, their innovative product. They reported the completion of dosing for the first patient at Beijing Hospital, marking the successful conclusion of the observation period.

This achievement is part of a Phase I/II clinical trial designed to evaluate NouvNeu001's safety, tolerability, and efficacy in treating moderate to advanced Parkinson's disease. The trial has begun at both Beijing Hospital and Zhongnan Hospital, with the first patient completing dosing.

Dr. Cai, iRegene's Chief Medical Officer, highlighted the significance of this milestone in the company's development.

NouvNeu001 is a chemically induced human dopaminergic neuron precursor derived from iPSC, wholly owned by iRegene. It is the world's first iPSC-based and chemically induced universal cell therapy product. NouvNeu001 is designed to optimize neuronal subtypes through chemical induction, establishing connections with existing neurons upon transplantation to enhance cellular secretion functions and address the original lesion, offering comprehensive therapeutic effects.

The National Medical Products Administration (NMPA) of China approved the Phase I/II clinical trial of NouvNeu001 on August 2, 2023. The trial, aimed at evaluating safety, tolerability, and efficacy in treating moderate to advanced Parkinson's disease, commenced successfully at Beijing Hospital in early January 2024. More details about the trial can be found on clinicaltrials.gov (NCT#06167681).

iRegene Therapeutics is a pioneering biotech company focused on utilizing "AI + chemical induction" for cell-specific functional remodeling. Leveraging this platform, iRegene has developed a robust pipeline of universal iPSC-derived products. The company is dedicated to advancing universal cell therapy products and introducing novel treatment options for traditionally challenging neurodegenerative diseases such as Parkinson's disease and blindness.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!